Eikon Therapeutics, INC

Eikon Therapeutics announced the resignations of two board members, Leon Chen and Joshua Wolfe, effective July 31, 2026.

Eikon Therapeutics presented updated clinical trial data for its EIK1001 and EIK1003 programs at the 2026 ASCO Annual Meeting, showing encouraging response rates and tolerability.

Eikon Therapeutics reported a larger 2025 net loss, completed Phase 2 enrollment for EIK1001 in first-line NSCLC, and strengthened liquidity with a $381.2 million upsized IPO, guiding cash runway into 2H 2027.

Eikon Therapeutics, Inc. filed its Form 10-Q for the quarter ended March 31, 2026, detailing ongoing clinical development, a significant increase in R&D expenses, and a substantial cash position post-IPO.

Eikon Therapeutics reported a larger 2025 net loss while advancing its oncology pipeline, closing a $349M IPO in February 2026 and guiding cash runway into 2H 2027 despite a disclosed material weakness and a license dispute.

Eikon Therapeutics' Chief Operating Officer, Michael A Klobuchar, was granted 87,157 stock options with a $14.88 exercise price.

Eikon Therapeutics Director Robert Luther Huffines was granted 25,873 stock options with an exercise price of $14.88, vesting monthly over four years.

Eikon Therapeutics Director Kenneth C. Frazier has acquired 25,873 stock options with an exercise price of $14.88, vesting monthly over four years.

Eikon Therapeutics' CEO, Roger M. Perlmutter, was granted 268,176 stock options with an exercise price of $14.88, vesting over four years.

Eikon Therapeutics, Inc. granted 67,044 stock options to Benjamin Bruno Thorner, General Counsel and Chief Business Officer, with an exercise price of $14.88.

Eikon Therapeutics' Chief Medical Officer, Roy D. Baynes, was granted 134,088 stock options with an exercise price of $14.88, vesting over 48 months.

The Column Group and its affiliates, including managing partners Tim Kutzkey and Peter Svennilson, reported an aggregate beneficial ownership of 11.6% in Eikon Therapeutics, Inc. following recent IPO purchases and preferred stock conversions.

Investment firm Innovation Endeavors has reported a 6.2% beneficial ownership stake in Eikon Therapeutics, Inc. as of March 31, 2026.

Dr. Roger M. Perlmutter has filed a Schedule 13G reporting beneficial ownership of 5.2% of Eikon Therapeutics, Inc. common stock.

FMR LLC and Abigail P. Johnson have jointly reported beneficial ownership of 7.1% of Eikon Therapeutics Inc.'s common stock as of March 31, 2026.

Foresite Capital and its affiliates disclose a combined 7.7% beneficial ownership in Eikon Therapeutics, Inc. common stock.